NCT02874573View on ClinicalTrials.gov

Tocilizumab in Schizophrenia

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
SchizophreniaPsychotic Disorders
Interventions
DRUG

Tocilizumab

Investigational agent

DRUG

Normal saline

Placebo

Trial Locations (1)

30912

RECRUITING

Augusta University, Augusta

Sponsors
All Listed Sponsors
collaborator

Brain & Behavior Research Foundation

OTHER

lead

Brian Miller

OTHER